A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Inclusion Criteria: Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. Adequate organ function and no very [...] n from egg donation for the duration of the study and for ≥ 907 days after the last dose of sonrotoclax or ≥1 30 daysmonth after the last dose of zanubrutinib, whichever is later. Only for participants with Chronic Lymphocytic Leukemia (CLL): Confirmed diagnosis of CLL, based on Hallek et al 2018, and [...] ory of prolymphocytic leukemia or Richter's transformation. Only for participants with Mantle cell lymphoma (MCL): Historically confirmed diagnosis of MCL based on the W [...] [...]

[...] on tumor lysis syndrome (TLS) and related toxicity signals. In the first part of the study, each ramp-up dosing schedule will first be tested in a small group of approximately 5 to 6 participants to assess safety and establish if the schedule is suitable for further testing in additional participants (schedule calibration). In the second part of the study, a [...] Sonrotoclax is an experimentala drug that works by blocking a protein called B-cell lymphoma-2 (BCL-2). This protein helps certain types of blood tumor cells to survive and grow. When sonrotoclax blocks BclBCL-2 it slows down or stops the g [...] [...]